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Focal Epilepsy (FE) accounts for more than the half of the total cases of all epileptic 
syndrome, around 60%. It can be caused by either genetic or acquired factors, such as 
brain trauma, tumors or inflammation. However, it is widely recognized to have a mostly 
a genetic basis. Mutations at the level of the GATOR1 complex components, DEPDC5, 
NPRL2 and NPRL3, were found in patients with FE, confirming the key role of the 
GATOR1 complex in the pathogenesis of various FE syndromes. In particular, it has been 
discovered that mutations of DEPDC5 gene are implicated in the 5%–37% of a broad 
range of FEs, both lesional or non-lesional and are associated with mTOR hyperactivity. 
The specific mechanism underlying the epileptogenic phenotype following DEPDC5 loss 
is far from being clear. The aim of this thesis is to deepen the impact of Depdc5 loss-of-
function at the cellular level, by focusing the attention on synaptic transmission and 
plasticity. In order to overcome the problem of embryonic lethality of Depdc5 full 
knockout in rodents, and the failure of Depdc5 constitutive heterozygous knockout mice 
to recapitulate the major epileptogenic traits, we used Depdc5-floxed mice and applied 
the Cre/LoxP technique to generate a model of Depdc5 cKO. We transfected primary 
cortical neurons obtained from Depdc5-floxed mice with lentiviruses expressing either 
active or inactive Cre recombinase and performed electrophysiological and biochemical 
experiments. We observed an increased in excitatory synaptic transmission and intrinsic 
excitability, while no difference occurred at the level of the inhibitory synaptic 
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transmission. Given the involvement of mTOR in the mechanism of plasticity and the 
effect of its dysregulation on synaptic transmission, we assessed whether Depdc5 loss 
could also have an impact at the level of the short-term plasticity (STP). However, no 
effects were found at the level of either excitatory or inhibitory synaptic transmission. 
The data suggest that Depdc5 loss mostly induces a strengthening of excitatory 
transmission at the post-synaptic level and by increasing the number of connections, 
without directly affecting pre-synaptic mechanisms. Thus, the enhanced excitatory 
synaptic transmission and increased intrinsic excitability could generate a synergistic 









2.1 Epilepsy: the history of a worldwide disease 
 
Epilepsy is one of the most diffuse and disabling neurological disorders, affecting 50 
million people worldwide. Before the first modern classification by Henri Gastaut in 
1970, seizures and the different epileptic diseases were not distinctly recognized. 
Gastaut, at the time Secretary-General of ILAE (International League Against Epilepsy) 
and member of the Commission an Classification, firstly defined the international 
recognized system and terminology that is still used and has evolved over the years 
(Gastaut, 1970).  
Thanks to the new advances in the neuroimaging, genomic technologies and molecular 
biology, this classification system underwent several changes and additions. Indeed, 
thanks to EEG recordings, which had a great impact on the clinical practice, ILAE 
published in 1981 a first classification of seizures, followed by updates of the epilepsy 
classification in 1985 and 1989, where the concept of an epilepsy syndrome was 
introduced (Pack, 2019). Later, another revision occurred in 2010 (Berg et al., 2010), 
with the final aim of an accepted definitive epilepsy classification, but a full consensus 
was difficult to reach. Thus, in 2014, ILAE assembled a new task force, which developed 
and published a new definition of epilepsy (Fisher et al., 2014) and in 2017 the final 
classification of seizures and the epilepsies (Fisher et al., 2017; Scheffer et al., 2017). 
    Compared to the 1980s classifications, the latest ILAE revised classification contains 
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modifications and several important additions to improve its intuitiveness, 
transparency and versatility, fundamental for creating a more efficient and effective 
communication between patients, their families, clinicians, and researchers (Falco-
Walter et al., 2018; Pack, 2019).  
 
2.2 Defining and classifying seizure, epilepsy and epileptic 
syndromes 
 
The epileptic seizure is define as “a transient occurrence of signs and/or symptoms due 
to abnormal excessive or synchronous neuronal activity in the brain” (Fisher et al., 
2017). The manifestation of excessive and hypersynchronous excitation of neuronal 
population leads to the transformation of the normal brain rhythms. Epilepsy is present 
in a patient when recurrent and unprovoked seizures occur (Fisher et al., 2014). Three 
main criteria have to be considered for epilepsy diagnosis: 
1) The patient should suffer from one or at least two unprovoked or reflex seizure less 
than 24h apart. 
2) One unprovoked or reflex seizure and a probability of further seizures similar to the 
general recurrence risk (> 60%) after two unprovoked seizures, in the next 10 years. 
3) An epilepsy syndrome (Fisher et al., 2014).  
Some people can experience an epilepsy syndrome, referred to a group of clinical 
characteristics that consistently occur together, with similar seizure types, age of onset, 
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EEG results, triggering factors that can be genetics or not, natural history, prognosis, and 
response to antiepileptic drugs (AEDs) (Stafstrom & Carmant, 2015). 
One can also heal from epilepsy, although it is not guarantee that it will not return. In 
particular, epilepsy is defined resolved when: (i) a patient who had an age-dependent 
epilepsy syndrome and who is older than the age in which the syndrome is active; or (ii) 
a patient who did not present any seizure for more than a 10 years and has been off all 
antiseizure medications for more than 5 years (Falco-Walter et al., 2018). 
 
2.2.1 Classification  
 
 
Figure 1. The ILAE 2017 operational classification of seizure types. (from Fisher et al., 2017). 
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Except for neonatal seizures, seizure classification can be applied to adults and children. 
The first distinction is according to the onset of seizures. They can be divided into focal, 
generalized or unknown seizures. A seizure is generalized when it originates at some 
point within the brain and rapidly distributes in bilateral networks in both hemispheres, 
whereas a focal seizure originates within a neuronal network in one hemisphere. When 
the onset of the seizure is ambiguous or unclear, but other manifestations are present, 
the seizure is of unknown onset (Falco-Walter et al., 2018). Another important feature 
of a seizure is awareness. It is particularly relevant for focal seizure, since during a 
generalized seizure awareness is impaired and is omitted in the generalized seizure 
classification. If awareness is impaired during any part of the seizure, we can classify the 
event as a focal impaired awareness seizure. For what concerns focal seizures, we can 
subclassify them according to the presence of motor and non-motor signs and 
symptoms at the onset. Usually, motor signs are dominating compared to non-motor 
signs. This is also true for generalized seizures, that can be classified into motor and non-
motor. In particular, the generalized motor seizure can be further subclassified into 
tonic-clonic or other motor. The same classification is applied to unknown onset seizure 
(Pack, 2019). 
 
2.2.2.1 Generalized seizures 
 
In a case of generalized epilepsy diagnosis, the patient would typically show generalized 
spike-wave activity on EEG. In particular, according to motor signs, generalized seizures 
can be distinguished into tonic-clonic, other motor seizures or non-motor generalized 
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seizures, indicating absence seizures. The diagnosis of generalized epilepsy is made on 
the basis of clinical evidence, supported by the finding of typical interictal EEG 
discharges (Falco-Walter et al., 2018; Scheffer et al., 2017).  
 
2.2.2.2 Focal Seizures 
 
One of the features for a first classification of focal epilepsy is patient’s awareness, 
meaning if the patient has knowledge and understanding of what is happening in his/her 
surroundings during the seizure. If during the seizure awareness is impaired, the event 
is classified as a focal seizure with impaired awareness. Another important aspect to 
consider is the motor or non-motor signs at the onset of the event. These early 
prominent features are important to consider when localizing the seizure onset or 
epileptogenic zone (Pack, 2019). The interictal EEG typically shows focal epileptiform 
discharges, but the diagnosis is made on clinical grounds, supported by EEG findings 
(Scheffer et al., 2017). 
 
2.2.2.3 Unknown seizures 
 
When the patient has epilepsy and all the related symptoms, but the type of epilepsy is 
difficult to determine, the term “unknown” is used. This could happen because of lack 
of information, no access to EEG or the EEG studies have been uninformative (Scheffer 
et al., 2017). Nevertheless, according to motor signs, seizures of unknown onset can be 
classified as motor or non-motor; otherwise, if information is insufficient, the seizure is 
considered unclassified (Pack, 2019). 
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2.2.2 Epilepsy etiology  
 
 
The causes of seizure onset can be different. The ILAE identified six etiologic categories: 
structural; genetic; infectious; metabolic; immune; unknown. Sometimes more than one 
cause can underlie the etiology of the seizure.  
 
1. Structural etiology: when a different structural condition or disease is thought to 
be the cause of seizures. These abnormalities can be visible through 
neuroimaging techniques and, together with electroclinical assessments, can be 
indicated as the likely cause of patient’s seizure. Structural lesions can be 
acquired by a stroke, trauma or infection event, or can have a genetic origin, like 
in tuberous sclerosis and malformation of cortical development (Falco-Walter et 
al., 2018; Scheffer et al., 2017). 
 
2. Genetic etiology: when epilepsy seems to be the direct result of a known or 
presumed genetic disorder in which seizures are the main manifestations. To 
contribute to epilepsy pathogenesis can be de novo mutations or copy number 
variations. However, the identification of the genetic etiology can be challenging, 
especially with many patients having variants of unknown significance (Falco-




3. Infectious etiology: it refers to a patient presenting epilepsy, not a patient with 
seizures due to an acute infection. Neurocysticercosis, HIV, CMV and cerebral 
toxoplasmosis can be considered infectious etiologies, many of which could also 
be considered as a structural etiology (Falco-Walter et al., 2018). 
 
4. Metabolic epilepsies: refers to a patient with epilepsy which is due to a metabolic 
derangement (Scheffer et al., 2017) 
 
5. Immune etiology: when an autoimmune disease is the cause of epilepsy onset. 
An example is antibody-mediated limbic encephalitis, which is an increasingly 
recognized cause of seizures in epilepsies of unknown origin (Falco-Walter et al., 
2018) 
 
6. Unknown category: refers to epilepsy whose etiology remains unclear (Falco-








2.3 Mechanisms of epileptogenesis and solutions for treating 
epilepsy 
 
Understanding the cellular and molecular mechanisms underlying the epileptogenic 
process is a fundamental step for developing new and effective therapies against 
epilepsy.  
Epileptogenesis occurs when a pathogenic event transforms physiological neuronal 
circuits into hyperexcitable circuits, disrupting their normal activity and leading to 
epileptic condition. Epileptogenesis acts at various levels in both neuronal and non-
neuronal cells in the brain, ranging from genetic and epigenetic alterations to molecular 
and structural changes (Devinsky et al., 2018). During epileptogenesis, transcription of 
voltage-gated and receptor-gated ion channels is altered. For example, transcription of 
low threshold T‑type calcium channels, such as Cav3.2 channels, is enhanced, inducing 
seizure during epileptogenesis. Interestingly, after genetic deletion of the gene in status 
epilepticus-exposed mice or pharmacological inhibition of T-type calcium channel by 
ethosuximide, spontaneous seizures, spike and wave discharges are decreased (Dezsi et 
al., 2013). Mutations in voltage-gated sodium channels also play an important role in 
epileptogenesis. Loss-of-function mutations in NaV1.1 cause Severe Myoclonic Epilepsy 
of Infancy (Dravet Syndrome). Mice with loss-of-function mutations in NaV1.1 channels 
show a strong impairment of sodium currents and action potential firing in hippocampal 
GABAergic inhibitory neurons, but with no notable effect on the excitatory pyramidal 
neurons, thus leading to hyperexcitability and seizures (Catterall, 2013). During 
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epileptogenesis, gene expression is also altered through epigenetic mechanisms such as 
DNA methylation, histone modification and microRNA (miRNA) expression. Gene 
activation occurs through DNA hypomethylation within 1 day of experimental status epi-
lepticus, whereas gene silencing induced by DNA hypermethylation has been observed 
in chronic epilepsy models and in patients with TLE (Henshall & Kobow, 2015). 
Epileptogenesis occurs at the molecular level too. Indeed, several signalling pathways 
are known to be altered during epileptogenic events. Among them, mTOR and BDNF 
signalling pathways are an example. BDNF–TrkB signalling alters the transcription of 
GABAA receptor subunits in granule cells of the hippocampal dentate gyrus, enhancing 
glutamatergic transmission while impairing the function of inhibitory synapses 
(Devinsky et al., 2018). Given the pivotal role of the mTOR pathway in cellular functions 
and neuronal excitability, it is not surprising that this signalling pathway can be involved 
in the  development of spontaneous seizures, representing an important target for both 
epileptogenesis and seizure pharmacotherapy. Accordingly, hyperactivated mTOR 
signalling has a main role in the pathogenesis of different animal models of acquired 
epilepsy and several studies have demonstrated that mTOR inhibitors, such as 
rapamycin, decrease the development of seizures preventing epileptogenesis-related 
mechanisms (Citraro et al., 2016). Interestingly, both pathways are involved also in 
structural changes of aberrant mossy fibre sprouting in the hippocampal granule cell 
layer, innervating inhibitory basket cells and decreasing neuronal excitability. 
Degeneration of excitatory mossy cells and the loss of inhibitory GABAergic and 
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neuropeptidergic hilar interneurons is likely linked to this anomalous sprouting 
(Devinsky et al., 2018).  
One of the main pharmacological treatment against epilepsy are antiepileptic drugs 
(AEDs). Antiepileptic drugs are currently the main solution for some forms of epilepsy, 
even though their activity is still limited and mostly active at the level of the 
excitatory/inhibitory imbalance. They act at different levels: they modulate voltage-
gated ion channels, like sodium, calcium and potassium channels, or enhancing 
inhibitory activity thus reducing the brain hyperexcitation. Given the pivotal role of 
voltage-gated ion channels in regulating neuronal excitability, some AEDs like 
phenytoin, carbamazepine and lamotrigine act at this level, limiting neuronal activity 
triggered by these channels. Others AEDs act through the enhancement of GABAergic 
inhibition, as barbiturates, benzodiazepine and vigabatrin and tiagabine (Kwan & Brodie, 
2006; Mula, 2018). 
Unfortunately, not all epilepsy forms are responsive to AEDs treatments. Despite the 
generation of new compounds every year for treating this disease, epilepsy remains 
uncontrolled in up to one-third of patients. Indeed, it has been estimated that around 
15 million people worldwide have drug-refractory epilepsy (Mula, 2016). The 
alternatives for these refractory epilepsies can be the surgical removal of the 
epileptogenic focus, or the stimulation of the vague nerve. Another option is the 
ketogenic diet, a very restrictive dietary regimen, consisting in high-fat, low-protein a 
low-carbohydrate diet. The exact mechanism on seizure suppression is still not univocal, 
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but mimicking a system that recreates the keto-acidotic state seems to have an effect 
on epilepsy (Kwan & Brodie, 2006).   
A recent and promising strategy to treat epilepsy is represented by gene therapy. 
Through the modification of endogenous genes, by targeting small brain regions without 
introducing the expression of foreign proteins, it is possible to restore the correct 
neuronal network activity with an approach that is generally considered as safe 
(Kullmann et al., 2014). For example, this approach has been used in a mouse model of 
chronic TLE. By applying the CRISPR/Cas9 toolbox, the endogenous Kcna1 expression 
has been increased in order to modulate neuronal activity, decreasing seizure initiation 
and rescuing behavioural and transcriptomic abnormalities. Thus, this promising tool 
can be used to regulate the expression of different genes, representing  the way to 
treating many possible epilepsy disorders associated with loss-of-function mutations 
and haploinsufficiency (Colasante et al., 2020). 
Indeed, in the last years, thanks to the recent advances in the neurobiology and genetics 
fields, specific genetic mutation have been found to be related to different forms of 
epilepsy, including focal epilepsy. In particular, mutations in genes encoding for the 
mTOR pathway components were found in tuberous sclerosis and other genetic 
syndromes, focal cortical dysplasia, non-lesional focal epilepsy, as well as post-traumatic 
epilepsy, making this pathway a potential novel target for epilepsy treatments (Myers & 
Scheffer, 2017).  
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2.4 The mTOR pathway and its regulation 
 
 
Figure 2. General overview of the mTOR pathway: upstream regulation, the protein complexes 
involved and downstream effectors (modified from Baldassarri et al., 2016). 
 
Mechanistic (previously known as mammalian) target of rapamycin, mTOR, is a well 
conserved 289 kDa PI 3-kinase (PIKK) and it is characterized by serine-threonine kinase 
activity.  
Genetic screening in the early ‘90s identified for the first time TOR in the budding yeast 
Saccharomyces cerevisiae, as the mediator to the inhibitory effect of rapamycin on the 
growth process. Shortly thereafter, the mammalian ortholog was isolated using FKBP12-
rapamycin affinity purification (Bockaert & Marin, 2015; González & Hall, 2017). mTOR 
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forms two structural and functional distinct complexes named mTOR complex 1 
(mTORC1) and mTOR complex 2 (mTORC2), respectively. Both mTOR complexes are 
large, with mTORC1 having six and mTORC2 seven known protein components. mTORC1 
is the best characterized of the two complexes and together with mTORC2 shares the 
catalytic mTOR subunit, mammalian lethal with sec-13 (mLST8), DEP domain containing 
mTOR-interacting protein (DEPTOR) and the Tti1/Tel2 complex. Regulatory-associated 
protein of mammalian target of rapamycin (Raptor) and proline-rich Akt substrate 40kDa 
(PRAS40) take part specifically in mTORC1, while rapamycin-insensitive companion of 
mTOR (Rictor), mammalian stress-activated map kinase-interacting protein 1 (mSin1) 
and protein observed with Rictor 1 and 2 (protor1/2) participate only in mTORC2. 
(Laplante & Sabatini, 2012) . 
The role of mTOR is to sense and integrate diverse intra- and extra-cellular signals to 
regulate a variety of cellular processes, ranging from cell growth to metabolism and 
survival, mainly through the regulation of gene and protein expression (Ryther & Wong, 
2012). In particular, mTORC1 senses nutrients such as glucose, amino acids, oxygen, ATP 
and growth factors. All this cues activate a pathway controlling a variety of cellular 
processes, including protein and lipid synthesis and autophagy (Laplante & Sabatini, 
2012). 
Compared to mTORC1, the mTORC2 pathway is less defined. mTORC2 is insensitive to 
nutrients, but it is able to respond to growth factors like insulin and thus controls cell 
survival, apoptosis, cell proliferation and cell shape. Moreover, since the acute 
treatment with rapamycin does not alter mTORC2 signaling as it does with m TORC1, 
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this complex was originally thought to be rapamycin-insensitive. However, long-term 
treatment with rapamycin reduces mTORC2 signaling in some cell types by suppressing 
mTORC2 assembly, but this mechanism is far from being clear (Laplante & Sabatini, 
2012).  
 
2.4.1 Upstream regulation of mTORC1 
 
The integration of diverse intra- and extra-cellular clues activating mTORC1 allows this 
protein complex to orchestrate a variety of physiological effects and control major cell 
processes, including protein and lipid synthesis and autophagy. The generation of a 
variety of different outcomes is therefore possible by the involvement of various 
effector pathways. 
The majority of the pathways that control both positively and negatively mTORC1 
involve the heterodimer consisting of tuberous sclerosis 1 (TSC1; also known as 
hamartin) and TSC2 (also known as tuberin). TSC1/2 is indeed a key upstream regulator 
of mTORC1 and exerts its function as a GTPase-activating protein (GAP) for the Ras 
homolog enriched in brain (Rheb) GTPase. The GTP-bound form of Rheb directly 
interacts with mTORC1 and strongly stimulates its kinase activity. As Rheb GAP, TSC1/2 
negatively regulates mTORC1 by converting Rheb into its inactive GDP-bound form 
(Laplante & Sabatini, 2012).   
The canonical activation of the mTOR pathway by growth factors, such as such as insulin 
and insulin-like growth factor 1 (IGF1), starts from the activation of tyrosine kinase 
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receptors (RTKs) that stimulate the PI3K and Ras pathways. The effector kinase of this 
pathway, Akt, extracellular-signal-regulated kinase 1/2 (ERK1/2), and ribosomal S6 
kinase (RSK1) inactivate the heterodimer TSC1/TSC2 by direct phosphorylation and thus 
result in mTORC1 activation (Bockaert & Marin, 2015; Laplante & Sabatini, 2012). 
Similarly to the mechanism of mTORC1 pathway activation by growth factors, pro-
inflammatory cytokines, like tumor necrosis factor-α (TNFα), induce phosphorylation of 
TSC1 by IκB kinase β (IKKβ), causing TSC1/2 inhibition (Laplante & Sabatini, 2012). 
Also low energy levels, hypoxia and DNA damage signal to mTORC1 through TSC1/2. In 
particular, the signaling pathway involves adenosine monophosphate-activated protein 
kinase (AMPK). AMPK phosphorylates TSC2 and increases its GAP activity towards Rheb 
and, being in direct contact with mTORC1, phosphorylates Raptor, leading to mTORC1 
inhibition. 
 Low-oxygen levels lead to the expression of transcriptional regulation of DNA damage 
response 1 (REDD1), which activates TSC2 function through a mechanisms that is not 
fully understood, while DNA damage also signals to mTORC1 through multiple 
mechanisms requiring p53-dependent transcription. DNA damage also induces the 
expression of Tsc2 and phosphatase and tensin homolog deleted on chromosome 10 
(Pten), inducing the downregulation of the PI3K-mTORC1 axis (Bockaert & Marin, 2015; 
Laplante & Sabatini, 2012). 
The TSC1/2 complex is not involved in the amino acid-mediated mTORC1 activation. 
Indeed, another heterodimer, composed of RagA/B and RagC/D, is needed to induce 
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mTORC1 translocation from the cytosolic compartment to the lysosome surface, where 
it can be activated by GTP-Rheb (Laplante & Sabatini, 2012).  
Another protein complex involved in the amino acid sensing branch is GATOR1, an 
upstream inhibitor of mTORC1. It is a GTPase Activating Protein (GAP) for RagA, 
consisting of Depdc5, NPRL2 and NPRL3 (Shen et al., 2018). GATOR1 activity is inhibited 
by GATOR2 protein complex, leading to the opposite effect of m TORC1 activation. 
(Bockaert & Marin, 2015; Shen et al., 2018). Recently, mutations in genes encoding 
GATOR1’s components have been found to be associated with several genetic focal 
epilepsy (FE) syndromes, including autosomal dominant nocturnal frontal lobe epilepsy 
(ADNFLE), familial temporal lobe epilepsy (FTLE), dominant epilepsy with auditory 
features (ADEAF), and familial focal epilepsy with variable foci (FFEVF) (Baldassari et al., 
2016). 
 
2.4.2 Downstream effects of mTORC1 activation 
 
Several studies in the last years, including large phosphoproteomic screens, identified 
new potential targets of mTORC1 (Switon et al., 2017). Protein synthesis is one the 
process known to be regulated by mTORC1 activity, yet poorly characterized. Given the 
pivotal role of protein synthesis in cell metabolism, the regulation of this process occurs 
based on nutrient disposal and general conditions of the cell. mTOR kinase is the main 
factor that links the energy state of the cell to protein translation. In the canonical 
pathway, mTORC1 directly interacts and phosphorylates the translational regulators 
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eukaryotic translation initiation factor 4E (eIF4E) binding protein 1 (4E-BP1) and 
ribosomal S6 kinase 1 (S6K1). Induction of protein synthesis occurs through inhibition of 
4E-BP1 with the subsequent release of inhibition of eIF4E. On the other hand, S6K1 
promotes protein synthesis by increasing mRNA biogenesis, as well as translational 
initiation and elongation by phosphorylating ribosomal protein S6 (Laplante & Sabatini, 
2012; Sadowski et al., 2015). 
mTORC1 not only promotes protein synthesis, but it is also involved in the synthesis of 
lipids required to generate membranes for proliferating cells. To do so, mTORC1 acts on 
the sterol regulatory element binding protein 1/2 (SREBP1/2) transcription factors 
regulating the expression of numerous genes involved in fatty acid and cholesterol 
synthesis (Laplante & Sabatini, 2012). 
mTORC1 activity negatively controls the initiation of macro-autophagy, and the latter 
process can be induced either through mTORC1 inhibition with rapamycin or amino acid 
starvation. mTORC1 inhibits the autophagic process through the inhibition of the ULK1 
complex (Unc-51- like kinase 1 [ULK1]–autophagy-related protein 13 [Atg13]–FAK family 
kinase-interacting protein of 200 kDa [FIP200] complex and autophagy/Beclin-1 
regulator 1 [AMBRA]). Another mechanism through which mTORC1 regulates macro-
autophagy occurs though the phosphorylation of the transcription factor EB (TFEB), 
which regulates the expression of some genes involved in autophagosome biogenesis 




Overall, the mTOR pathway plays a key role in the physiological regulation of normal 
cellular function and processes, while its dysregulation leads to the development of 
disease under pathological conditions such as type 2 diabetes, inflammation, cancer, 
and cardiovascular pathologies. Furthermore, alteration of the normal mTOR signaling 
is involved in a variety of neurological diseases, including epilepsy, psychiatric and 
neurodegenerative disorders (Citraro et al., 2016). The name ‘mTORopathies’ 
collectively indicates a number of clinical syndromes in which mTOR regulation is altered 
(Griffith & Wong, 2018). Given the wide range of neuronal and non-neuronal functions 
controlled by the mTOR signaling pathway, it is not surprising that its regulation through 
pharmacological inhibitors, such as rapamycin and its derivatives, has controversial 
effects. In the murine genetic TSC model, suppressing mTOR activity using rapamycin 
administered in prenatal, postnatal and pre/postnatal (combined) temporal windows 
reduce seizure frequency, neuronal and glial pathology, thus interfering with the 
epileptogenic process (Way et al., 2012). Surprisingly, the animals treated with the 
combined therapy do not perform well as postnatally-treated animals in learning and 
memory tasks, indicating a necessary optimization of the timing and dosage of the 
rapamycin treatment (Way et al., 2012). On the other hand, a phase III clinical trial 
demonstrated that a rapamycin-derived compound, Everolimus, exhibited anti-seizure 
activity in a cohort of patients affected by TSC (French et al., 2016). Moreover, limitation 
of mTOR activity also affects growth and proliferation, protein and lipid synthesis, cell 
cycle and autophagy, all processes that are necessary for correct physiology and survival 
of cells. Thus, the efficacy of rapamycin and its pharmacological derivatives in both 
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animal models and patients is still debatable and the precise mechanism of action 
underlying their therapeutic effects could by influenced by the animal model and the 










Figure 3. Different roles of mTORC1 in the brain and its regulation by GATOR1 complex (modified 
from Baulac, 2014). 
Given the pivotal role of mTORC1 in regulating numerous cellular processes, it is not 
surprising that it plays a major role also in controlling brain physiology and pathology. 
Besides its implication in autophagy, cell size, survival, migration and proliferation, it is 
a main regulator of some more specific neuronal processes, such as axonal sprouting 
and regeneration, myelination, dendritic spine growth and ionic channels and 
neurotransmitter receptor expression. mTORC1 activity is able to regulate higher 
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physiological functions such as neuronal excitability, neuronal survival, synaptic 
plasticity and cognition; therefore, mutations of genes coding for proteins involved in 
the mTOR pathway, or alteration in their expression level, could underlie different brain 
diseases. Some of these are psychiatric diseases such as depression, mental retardation, 
schizophrenia, Down syndrome, and autism spectrum disorders (ASD), including 
tuberous sclerosis (TSC), Fragile X, neurofibromatosis, and Rett syndrome. Alteration of 
mTOR has also been involved in neurological diseases, particularly in different forms of 
epilepsies, Parkinson’s disease (PD), Alzheimer’s disease (AD), and brain trauma 
(Bockaert & Marin, 2015). 
 
2.4.3.1 Neuronal progenitor proliferation and differentiation  
 
The central role of mTOR in neuronal differentiation is well established. Indeed, PI3-
kinase/TOR signaling during neurogenesis in the developing mouse and chick is 
necessary for the correct neuronal development. Mice lacking PDK1/PKB activity and 
chick neural tube exposed to PI3-kinase or TOR inhibitors showed disrupted 
neurogenesis (Fishwick et al., 2010). Deletion of the upstream inhibitor of mTORC1, 
REDD1, induced cell cycle exit impairing neuronal differentiation and migration 
(Malagelada et al., 2011), while deletion of PTEN, inhibitor of the Akt-mTORC1 pathway, 
triggers constitutive neurogenesis in the subventricular zone (SVZ) neurogenic niche in 
the adult brain (Gregorian et al., 2009). Moreover, it has been demonstrated the key 
role of enhancer of zest homolog2 (Ezh2) in the regulation of PTEN-Akt-mTOR pathway 
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in SGZ, is essential not only for hippocampal neurogenesis, but also for preserving 
cognitive functions (Zhang et al., 2014). 
 
2.4.1.2 Neuronal morphogenesis and growth  
 
Neuronal hypertrophy if a characteristic of most brain pathologies in which an 
hyperactivation of mTORC1 is present, such as in Tuberos Sclerosis (TS) with mutations 
in TSC1 or TSC2, Fragile X syndrome (mutations in FMRP) or Cowden syndrome 
(mutations in PTEN), hemimegalencephaly and ganglioglioma (Bockaert & Marin, 2015). 
Hypertrophic cells have a soma 1.5-2 times larger than normal cells and have been found 
in cortex, hippocampus and cerebellum. Rapamycin administration revertes the 
phenotype, confirming the mTORC1 hyperactivation-dependence of this process. In 
human mTORopathies, this effect is especially evident in patients affect by TSC, 
displaying giant cells within the tuber (Lasarge & Danzer, 2014), or in patient suffering 
from Focal Cortical Dysplasia (FCD), a condition characterized by the presence of the so 
called “balloon cells”.  
Alteration in cell shape and size leads to several consequences both at the micro- and 
macroscopic level. Indeed, at the single cell level, an increased soma area decreases the 
cell input resistance and increases the total cell capacitance, while at the macroscopic 
level, hypertrophy can lead to increased brain size and loss of organization of the cortical 
layers (Lasarge & Danzer, 2014). 
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2.4.1.3 Dendritic arborisation, synaptic physiology and plasticity processes 
 
The structure of the dendritic tree is essential for precise signal processing. Indeed, 
changes in dendritic thickness induced by mTOR dysregulation can potentially lead to an 
altered synaptic input integration (Lasarge & Danzer, 2014). It has been demonstrated 
that the dendritic growth and branching process is regulated through PI3K/PTEN–mTOR 
pathway and that the silencing of PTEN triggers an increase in the number and total 
length of dendrites, and an increase in branching complexity (Jaworski et al., 2005). 
 mTORC1 activation is also involved in the regulation of ion channel expression. It has 
been shown that, upon m TORC1 activation, NMDA receptor activation occurs and, in 
turn, inhibits local Kv1.1 synthesis, likely via PI3K activation by Ca2+ entry, thus 
facilitating action potential generation (Raab-Graham, Haddick, Jan, & Jan, 2006). 
mTORC1 is also involved in surface expression of AMPA receptors (AMPARs) in cortical 
neurons, enhancing synaptic activity. Indeed, a rapamycin-sensitive increase in the 
expression of AMPARs subunits GluR2/3 has been observed in primary cortical neurons 
(Wang, Barbaro, & Baraban, 2006). On the opposite, in hypothalamic pro-
opiomelanocortin (POMC) neurons, an increase of total KATP channel conductance is 
triggered by the age-dependent increase in mTORC1 activity, thus silencing the activity 
of POMC neurons  and contributing to age-dependent obesity (Yang et al., 2012). Given 
its role in the regulation of protein expression, a fundamental process occurring during 
long-term plasticity, it is not surprising that mTORC1 acts as a regulator in this 
mechanism too, as shown in different organisms such as Aplysia, crayfish, and mammals. 
In particular, late-stage Long Term Potentiation (L-LTP), in which transcription and 
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translocation of new proteins is needed, is a cAMP- and mTORC1-dependent process 
(Cammalleri et al., 2003). cAMP synthesis could lead to m TORC1 activation by inducing 
Ca2+ entry from NMDAR and activation of Ca2+ -dependent adenylyl cyclase. On the other 
hand, cAMP production triggers BDNF release, that in turn activates the PI3K-Akt-mTOR 
pathway (Bockaert & Marin, 2015). However, some contradictory data exist, according 
to which administration of rapamycin does not block L-LTP in thedentate gyrus in vivo 





2.5 GATOR1 complex and its key role in Focal Epilepsy  
 
Recent studies revealed that Focal Epilepsy (FE) accounts for more than the half of the 
total cases of all epileptic syndromes, around 60%. It can be caused by both genetic and 
acquired factors, but in most cases it has a genetic basis (Baldassari et al., 2016; Boillot 
& Baulac, 2016; Téllez-Zenteno & Hernández-Ronquillo, 2012). Familial Focal Epilepsies 
(FFEs) include several forms of inherited autosomal dominant, non-lesional, focal 
epilepsies. These can be distinguished into autosomal dominant nocturnal frontal lobe 
epilepsy (ADNFLE), familial temporal lobe epilepsy (FTLE), dominant epilepsy with 
auditory features (ADEAF), and familial focal epilepsy with variable foci (FFEVF).  
The results of earlier genetic studies for ADNFLE, a syndrome characterized by clusters 
of motor seizures occurring mostly during sleep, revealed a correlation between 
mutation in genes encoding for ion channels and neurotransmitter receptors. Indeed, in 
1995, the first  mutated gene related to an inherited form of focal epilepsy, ADNFLE, was 
identified (Steinlein et al., 1995). The gene was CHRNA4, encoding for a subunit of the 
nicotinic acetylcholine receptor (nAChR). Later studies identified mutations in other 
nAChRs subunits, CHRNB2 and CHRNA2 already related to a subset of ADNFLE (Boillot & 
Baulac, 2016). More recently, mutations in the potassium channel KCNT1 gene have 
been found to associate with ADNFLE.  The first mutation in a gene other than ion 
channels or neurotransmitter receptors is LGI1, which was identified in families with 
ADEAF, a syndrome presenting focal seizures with typical auras and/or auditory 
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symptoms suggesting a lateral temporal onset. Mutations in this gene account for 
almost 50% of ADEAFs (Ottman et al., 2004).  
Only recent studies discovered the link between diverse focal epileptic phenotypes, 
ranging from apparently non-lesional focal epilepsies to malformation-associated focal 
epileptic syndromes with mutation in genes encoding for components involved in the 
regulation of the mTOR pathway, especially the components of the GATOR1 complex, 
Depdc5, NPRL2/3 (Baldassari et al., 2019). 
In 2013, mutations in Depdc5 gene were first identified in seven out of eight FFEVF 
families linked to chromosome 22q12. This mutations were found to be implicated in 
the 5%–37% of a broad range of FEs, including NFLE and TLE (Dibbens et al., 2013; Ishida 
et al., 2013). Few years later, in 2016, mutations in NPRL2 and NPRL3 were found in 
patients with FE, confirming the key role of the entire GATOR1 complex in the 
pathogenesis of FE syndromes (Ricos et al., 2016; Sim et al., 2016). More recently, a 
bialellic 2-hit mutational mechanism, with brain somatic and germline mutations of the 
DEPDC5 gene, was observed in resected brain tissue of patients with the most severe 
symptomatology, including focal cortical dysplasia type II (FCD type II; Ribierre et al., 
2018). To demonstrate the causality of this DEPDC5 brain mosaic inactivation, they 
performed in utero electroporation using CRISPR-Cas9 editing in mice, generating an 
animal model that finally recapitulated FE with cortical malformation and severe 
phenotype, indicating that loss of heterozygosity is necessary for the establishment of 
epilepsy-associated FCD observed in patients (Ribierre et al., 2018).  
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Overall, these data indicate that mutations in genes encoding the GATOR1 complex can 
be defined as the most frequent genetic cause of FEs, globally underlying the 9% of the 
cases. This finding suggests the possibility that defects in the same molecular pathway 








2.6 The DEPDC5 gene: role and function 
 
DEPDC5 gene is located on chromosome 22q12 and encodes the 1603–amino acid 
protein Disheveled, Egl-10, and Pleckstrin (DEP) domain-containing 5 (DEPDC5). The 
protein presents five domains, N-terminal domain (NTD), SABA (previously annotated as 
DUF3608, Domain of Unknown Function 3608), SHEN, DEP and the C-terminal domain 
(CTD) that have been resolved and visualized for the first time only recently (Shen et al., 
2018). It is the largest subunit of the GAP Activity Toward Rags complex 1 (GATOR1), an 
inhibitor of the mTORC1 pathway, together with NPRL2 and 3.  
DEPDC5 is connected to NPRL3 by NPRL2, which in vitro acts as a GTPase-activating 
protein (GAP) for Rag GTPases, in particular Rag A/B. The interaction between DEPDC5 
and the Rag heterodimer blocks the GATOR1 ability to stimulate GTP hydrolysis, while 
NPRL2-NPRL3 and RagA interaction executes the GAP activity. Rag GTPases are present 
in heterodimers of RagA or RagB, which are highly homologous with either RagC or 
RagD. Their function is to mediate amino acid signaling to mTORC1 and the amino acid-
induced re-localization of mTOR within the endomembrane system of the cell (Bar-Peled 
et al., 2013; Sancak et al., 2008). Components of both GATOR complexes are highly 
conserved across evolution and have been well characterized in yeast S. cerevisiae 
(Algret et al., 2014; Dokudovskaya & Rout, 2015). In yeast, the DEPDC5 orthologous 
protein Sea1 (also known as Iml1) is part of the SEA complex with Npr2 and Npr3, and 
functions as a GAP complex to inhibit the Rag-dependent activation of TORC1 (Panchaud 
et al., 2013).  
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The recent discovery of an association between mutations in Depdc5 gene with a broad 
range of FEs make Depdc5 a promising and potential therapeutic target for epilepsy 






2.7 Models of DEPDC5 deficiency  
 
 
Given the major involvement in DEPDC5 gene and related mutations in FEs, an increasing 
number of studies focused their attention in characterizing DEPDC5 loss-of-function 
models. In 2016, Marsan and colleagues investigated the effect of in vivo Depdc5 loss in 
rat. By using TALEN-mediated Depdc5 knock out rat, they demonstrated that 
constitutive deletion of Depdc5 is embryonically lethal, while the heterozygous rats 
develop normally in the absence of spontaneous electroclinical seizures, but presenting 
cortical neuron excitability and firing patterns (Marsan et al., 2016). The in vivo effect of 
Depdc5 deficiency was further investigated by Hughes and colleagues in 2017, 
generating mice with loss-of-function alleles using CRISPR/Cas9 mutagenesis. Their 
experiments were in line with the previous evidence by Marsan: Depdc5 null mice 
showed embryonal death, growth defects in different organs and systems and mTORC1 
hyperactivation in embryonic brain lysates (Hughes et al., 2017). In order to overcome 
the problem of embryonic lethality in germline knockout Depdc5 rodent model, a 
neuron-specific Depdc5 cKO mouse by Cre-recombination under the Synapsin1 
promotor (Depdc5cc+) was developed. These mice actually survive to adulthood, but 
with a reduced survival compared to control littermates. They present morphological 
malformations in the form of larger brains with increased and dysplastic cortical neurons 
size, hyperactivation of the mTORC1 pathway and increased susceptibility to both 
spontaneous and provoked seizure (Yuskaitis et al., 2018). Moreover, the chronic 
inhibition of the mTORC1 pathway with rapamycin seems to significantly prolong the 
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survival of Depdc5cc+ mice, by rescuing the morphological abnormalities and mTORC1 
hyperactivation (Yuskaitis et al., 2019). Depdc5 loss-of-function has also been studied in 
lower animal models, such as Zebrafish. By a morpholino oligonucleotide-mediated 
Depdc5 knockdown, authors showed an increase in neuronal activity (de Calbiac et al., 
2018), while in another work, a zebrafish full knockout model showed increased seizure 
propensity, premature death and defects in the GABAergic system (Swaminathan et al., 
2018). Alteration of the GABAergic system have also been found in a novel mouse model 
of Depdc5 deficiency generated by conditional deletion of Depdc5 in dorsal 
telencephalic neuroprogenitor cells. These neurons, apart from showing enlarged soma 
size and mTORC1 hyperactivity, also present impaired postsynaptic responses to 
GABAergic inputs, which may generate hyperexcitability and represent the 
epileptogenic mechanism (Klofas et al., 2020).  
Recently, it has been proposed that a “two-hit” mosaic inactivation, brain somatic and 
germline, of the DEPDC5 gene is present in patients with the most severe phenotypes. 
To demonstrate this hypothesis, Ribierre and colleagues induced Depdc5 brain mosaic 
inactivation using CRISPR-Cas9 editing and in utero electroporation in the mouse cortex, 
recapitulating focal epilepsy with FCD and SUDEP-like events (Ribierre et al., 2018). All 
these experimental models were able to reproduce some of the main clinical features 
of DEPDC5-related epilepsy; however, the mechanisms underlying the morphological 
and physiological effect of DEPDC5 deficiency on synaptic transmission, plasticity and 
connectivity are still to be clarified.  
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In this contest, we decided to further investigate the mechanisms by which DEPDC5 loss-
of-function triggers neuronal and network hyperexcitability. In our first study published 
at the beginning of the 2020, we investigated the cellular mechanisms of 
hyperexcitability by comparing the constitutively heterozygous Depdc5 knockout mouse 
versus various levels of acute Depdc5 deletion (≈40% and ≈80% neuronal knockdown of 
Depdc5 protein) by RNA interference in primary cortical cultures. While heterozygous 
Depdc5+/− neurons show a weaker phenotype, acutely knocked-down neurons exhibit a 
strong dose-dependent phenotype, showing mTOR hyperactivation accompanied by 
increased soma size, dendritic arborization, excitatory synaptic transmission and 
intrinsic excitability. These results highlights the importance of the temporal dynamics 
of Depdc5 knockdown in triggering the phenotypic changes, reminiscent of the somatic 
second-hit mechanism in patients with focal cortical dysplasia and suggesting the 
importance of DEPDC5 in the developmental process. Moreover, we observed synaptic 
alterations only at the level of excitatory synapses, with no effect on the inhibitory 
synapses. These evidences, strengthen the hypothesis of an excitation/inhibition 
imbalance triggering epileptogenesis and the pivotal role of DEPDC5 in 









Figure 4. Acute Depdc5 knockdown leads to a robust neuronal and synaptic phenotype. It 
increases neuronal soma size and dendritic arborizations, alters synaptic connectivity and 
induces an excitation/inhibition imbalance at the synaptic level. The hyperexcitability of 




3. Aim of the thesis 
 
 
The aim of this PhD project is to deepen the pathological role of Depdc5 loss on synaptic 
transmission and plasticity. In order to address this issue, we applied the Cre/LoxP 
technique, characterizing the effect of Depdc5 conditional knockout by performing 
electrophysiological and biochemical experiments on primary cortical neurons obtained 
from Depdc5-floxed pups. By transfecting cortical neurons with lentivirus expressing 
active or inactive Cre recombinases, we observed the effect of Depdc5 cKO at the level 
of both excitatory and inhibitory synapses, analyzing synaptic transmission and short-
term plasticity processes. Our data suggest that the Depdc5 loss mostly induces a change 
at the level of synaptic connectivity, by increasing the number of excitatory synapses 










Dedpc5-floxed mice were kindly donated from Stephanie Baulac Lab (Paris Brain 
Institute - Institut du Cerveau – ICM) and bred at the IIT-San Martino animal facility. To 
detect homozygous Depdc5-floxed mice, genotyping was performed by PCR with the 
following primers Depdc5_F: AGCAAGATGACTTCCCTGCTCCAAGA, Depdc5_R: 
CTGTGCTCTCATTTCCAACCATCCCT. The colony was maintained and propagated in 
homozygosity. Constitutive heterozygous Depdc5 KO mice were obtained from the IMPC 
European Consortium at the Sanger Institute (UK) and bred at the IIT animal facility. 
EUCOMM/KOMP targeting strategy was based in the “knockout-first” allele (Tm1a) 
designed to be a knockout by splicing the cDNA to a LacZ cassette, which was inserted 
into the intronic region, between exons 4 and 5 of Depdc5 locus, creating a null allele of 
the gene (Skarnes et al., 2011). Genotyping was performed by PCR with the following 
primers Depdc5_F: GGTTTTAGTTTTTGGATTTGTTTCA, Depdc5_R: 
GCCTTTAATCCCAGCACTTG; 5mut-R1_Term: GAACTTCGGAATAGGAACTTCG, that were 
used to detect the WT (+/+) (Depdc5_F plus Depdc5_R product, 227 bp) and mutant 
(Depdc5_F plus CAS_R1_Termproduct, 129 bp) Depdc5 alleles and to genotype wild type 
(+/+) and heterozygous (+/−) mice. The colony was maintained and propagated in 
heterozygosity. Both Dedpc5-floxed mice and constitutive heterozygous Depdc5 KO 
mice were maintained on a 12:12 h light/dark cycle at a constant temperature (21 C°) 
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and relative humidity (60%). Drinking water and a complete pellet diet (Mucedola, 
Settimo Milanese, Italy) were provided to mice ad libitum. Two females were housed 
with one male in standard Plexiglass cages (33 x 13 cm), with sawdust bedding and metal 
top. After two days of mating, male mice were removed and dams were housed 
individually and daily checked for delivery. All the experiments were carried out in 
accordance with the guidelines established by the European Communities Council 
(Directive 2010/63/EU of March 4th, 2014) and were approved by the local Ethics 
Committee and the Italian Ministry of Health. 
 
Low-density and autaptic cultures of cortical neurons 
 
Low-density primary cortical neurons were obtained from postnatal Depdc5-floxed mice 
(P0-1), as previously described (Beaudoin et al., 2012; Valente et al., 2016). In brief, 
cortices were dissociated by enzymatic digestion in 0.25% trypsin for 6 min at 37 °C and 
mechanically triturated with a pipette and plated the desired density. For cell culture 
preparations, the following solutions were used: HANKS solution, prepared from HBSS 
(GIBCO 14170-088; red) supplemented with 10 mM HEPES, 30 mM D-glucose, 5 μg/ml 
Gentamycin, pH 7.4 with KOH; dissection solution, prepared from HANKS solution 
supplemented with 10% bovine serum albumin and 6 mM MgSO4*7H2O. Primary cortical 
neurons were plated at low density (100 cells/mm2) on 3.5-cm-diameter Petri dishes 
(Falcon® 35 mm) treated for 24 h with poly-L-lysine (0.1 mg/ml; Sigma-Aldrich) in borate 
buffer (0.1 M). For autaptic neurons, cells were plated at very low density (20 cells/mm2) 
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on microislands (40–300 μm diameter) obtained by spraying of poly-L-lysine (0.1 mg/mL) 
in buffer borate (0.1 M) on Petri dishes pre-treated with 0.15% agarose, as previously 
described (Chiappalone et al., 2009; Valente et al., 2012). Cells were grown in a culture 
medium consisting of Neurobasal A (Gibco™) supplemented with 2% B-27 (Invitrogen, 
Italy), 1 mM Glutamax, and 5 μg/ml Gentamycin and maintained at 37 °C in a humidified 
incubator with 5% CO2. 
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RNA extraction, retrotranscription and qRT-PCR 
 
Total cellular RNA was extract with TRIzol (Life Technologies) and RNA concentration 
was quantified by using the Nanodrop-1000 spectrophotomer (Thermo Scientific). cDNA 
was synthesized starting from 0.25 ug RNA with SuperScript IV Reverse Transcriptase kit 
(#180900010; Thermo Fisher) according to manufacturer’s instruction and used for qRT-
PCR. Gene expression was measured by quantitative real-time PCR using C1000 Touch 
Thermal Cycler (Bio-Rad) on a CFX96 Real time System following the manufacturer’s 
protocol. Real time qPCR analyses were perfomed using the SYBR Green I Master Mix 
(Roche), on a Lightercycler 480 (Roche), with the following protocol: 95 °C for 5 min; 10 
s at 95 °C/ 20 s at the specific annealing temperature (Ta) / 10 s at 72 °C for 45 cycles; 
melting curve (heating ramp from 55 °C to 95 °C) in order to check for amplification 
specificity. The following primers (final concentration 0.25 µM) and annealing were 
used: 
Depdc5_F: TGATGCCTACGATGCTCAAG, Ta= 64 °C;  
Depdc5_R: TGGCTCCTCACTTCCTCAGT, Ta= 64.1 °C;  
Gapdh_F: GATCATCAGCAATGCCTCCT, Ta= 59.8 °C; 
Gapdh_R: TGTGGTCATGAGTCCTTCCA, Ta= 61.7 °C; 
Relative gene expression was determined using the ΔΔCT method, normalizing data and 




Virus production and neuron transduction 
 
Sequences containing active or inactive Cre-recombinase were cloned into pLenti-PGK-
Cre-EGFP or pLenti-PGK-ΔCre-EGFP plasmids (Jaudon et al., 2020; Kaeser et al., 2011). 
The production of VSV-pseudo typed third-generation lentiviruses was performed as 
previously described (De Palma and Naldini, 2002). For all the experiments, 6 to 7 days 
in vitro (DIV) cortical neurons were infected at 10 multiplicity of infection (MOI). After 
24 hours from infection, half of the medium was replaced with fresh medium. 
Transduction efficiency was assessed by visual evaluation of GFP fluorescence. For 
rescue experiments, rapamycin (100 nM, LC Laboratories) and DMSO (Sigma-Aldrich) as 
control, were administered at the time of infection, without replacing the medium. 
 
Western blotting 
Whole brain from E12.4 mouse embryos or primary cortical neurons were used to obtain 
total cell lysates. Lysis buffer (150 mM NaCl, 50 mM Tris-HCl pH 7.4, 1 mM EDTA, 1% 
Triton X-100) enriched with protease and phosphatase inhibitor cocktails (Roche, 
Monza, Italy) was used to extract cells. Following 10 min of incubation on ice, cell lysates 
were collected and clarified by centrifugation for 10 min at 10,000 x g at 4 °C. Brains 
were dissected and pottered in liquid nitrogen, followed by a centrifugation at 1,000 x g 
for 10 min at 4 °C. To determine protein concentration, the BCA assay (Thermo Scientific) 
was used. Equivalent amount of proteins were subjected to SDS-PAGE on 10% 
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polyacrylamide gels and blotted onto nitrocellulose membranes (Whatman). Blotted 
membranes were blocked for 1 h using 5% milk in Tris-buffered saline (10 mM Tris, 150 
mM NaCl, pH 8.0) together with 0.1% Triton X-100 and incubated overnight at 4 °C with 
the following primary antibodies: rabbit anti-Depdc5 (1:1000, Abcam ab185565), rabbit 
anti-phosphorylated S6 protein (1:2000, Cell Signaling #5364), mouse anti-S6 (1:1000, 
Cell Signaling #2317) and mouse anti-actin (1:2000, Sigma-Aldrich A2228). Thereafter, 
membranes were washed and incubated for 1 h at room temperature (RT) with 
peroxidase-conjugated goat anti-mouse (1:3000; Bio-Rad) or anti-rabbit (1:5000; Bio-
Rad) antibodies. Bands were revealed with the ECL chemiluminescence detection 
system (Thermo Scientific) and the quantification of immunoreactivity was performed 
by densitometric analysis of the fluorograms.  
 
Patch-clamp recordings  
Whole patch-clamp were made from primary cortical neurons as previously described 
using a Multiclamp 700B/Digidata 1400A system (Molecular Devices, Sunnyvale, CA). 
Patch pipettes, prepared from borosilicate glass, were pulled and fire-polished to a final 
resistance of 4-5 M when filled with standard internal solution. For all the 
experiments, neurons were maintained in standard extracellular Tyrode solution 
containing (in mM): 140 NaCl, 2 CaCl2, 1 MgCl2, 4 KCl, 10 glucose, and 10 HEPES (pH 7.3 
with NaOH). For the analysis of neuronal excitability, D-(-)-2-amino-5-phosphopentanoic 
acid (D-AP5; 50 µM), 6-cyano-7 nitroquinoxaline-2,3-dione (CNQX; 10 µM), bicuculline 
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methiodide (30 µM), and (2S)-3-[[(1S)-1-(3,4-dichlorophenyl)ethyl]amino-2-
hydroxypropyl] (phenylmethyl)phosphinic acid hydrochloride (CGP58845; 5 µM) were 
added to block NMDA, non-NMDA, GABAA, and GABAB receptors, respectively. Current-
clamp recordings of action potential (AP) firing activity were performed at a holding 
potential of -70 mV and APs were induced by injection of 10 pA current steps lasting 500 
ms in morphologically identified pyramidal neurons. Excitatory neurons were identified 
by estimating the AP failure ratio evoked by short trains of high current steps at 
increasing frequency (Prestigio et al., 2019). The firing rate was calculated as the number 
of APs evoked by minimal current injection in 500 ms, whereas the instantaneous 
frequency was estimated as the reciprocal value of the time difference between the first 
two evoked APs. Current-clamp recordings of APs were acquired at 50 kHz and filtered 
at 1/5 of the acquisition rate with a low-pass Bessel filter. The number of elicited APs 
and the instantaneous frequency were analyzed using Clampfit 10.7 (Molecular Devices, 
Sunnyvale, CA) and Prism softwares. The shape properties of the first AP elicited by 
minimal current injection were analyzed by building time-derivatives of voltage (dV/dt) 
versus voltage plots (phase-plane plots), as previously described (Prestigio et al., 2019; 
Valente, Castroflorio, et al., 2016). Phase-plane plots were obtained and analyzed with 
the software OriginPro-8 (OriginLab Corp., Northhampton, MA, USA). For recording 
miniature excitatory postsynaptic currents (mEPSCs), bicuculline, CGP58845, D-APV, and 
tetrodotoxin (TTX; 300 nM) were added to the extracellular solution to block GABAA, 
GABAB, NMDA receptors and generation and propagation of spontaneous APs, while for 
recording miniature inhibitory postsynaptic currents (mIPSCs) bicuculline was replaced 
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with CNQX. The internal solution (K-gluconate) used for recording APs in current-clamp 
and mEPSCs in voltage-clamp configuration contained (in mM): 126 K gluconate, 4 NaCl, 
1 MgSO4, 0.02 CaCl2, 0.1 BAPTA, 15 glucose, 5 HEPES, 3 ATP and 0.1 GTP (pH 7.3 with 
KOH). The internal solution (KCl) used for mIPSC recordings contained in (mM): 126 KCl, 
4 NaCl, 1 MgSO4, 0.02 CaCl2, 0.1 BAPTA, 15 glucose. 5 HEPES, 3 ATP and 0.1 GTP (pH 7.3 
with KOH). All reagents were from Tocris, otherwise specified. Both mEPSCs and mIPSCs 
were acquired at a 10 kHz sample frequency and filtered at 1/5 of the acquisition rate 
with a low-pass Bessel filter. The amplitude and frequency of the miniature excitatory 
and inhibitory events were calculated using a peak detector function using appropriate 
threshold amplitudes and areas. The frequency, amplitude and kinetics of miniature 
PSCs were analyzed using the MiniAnalysis (Synaptosoft) and Prism (GraphPad Software, 
Inc.) softwares. All experiments were performed at RT. Evoked excitatory and inhibitory 
postsynaptic currents (eEPSCs/eIPSCs) were recorded in Tyrode, with addition 
bicuculline, D-APV for eEPSCs and D-AP5, CNQX and CGP58845 for eIPSCs. Recordings 
were performed using an EPC-10 amplifier (HEKA Electronic) and acquired at 10-20 kHz 
sample frequency and filtered at 1/5 of the acquisition rate with an 8-pole low-pass 
Bessel filter. The size of the readily releasable pool (RRP) and the probability release (Pr) 
were calculated using the cumulative amplitude analysis (Schneggenburger, Meyer, & 
Neher, 1999). RRP was determined by summing up peak PSC amplitudes during 40 
repetitive stimuli applied at 40 Hz (1s@40Hz). The cumulative amplitude profiles of the 
last 15–20 data points were fitted by linear regression and backextrapolated to time 0. 
The intercept with the Y-axis gave the RRP and the ratio between the amplitude of the 
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first ePSC (I1) and RRP yielded the Pr. To study the response to paired-pulse protocols, 
we applied two consecutive stimuli at increasing interpulse intervals (20-1000 ms). Data 




To fix primary cortical neurons, 4% formaldehyde, prepared from paraformaldehyde in 
0.1 M phosphate buffer (PB) at a pH 7.4, was used for 20 min at RT. Fixed neurons were 
immunostained for specific pre/postsynaptic markers of excitatory and inhibitory 
synapses. Briefly, several washes in PBS, cells were permeabilized and blocked for 30 
min in 0.05% Triton X-100 and 10% normal goat serum (NGS) in phosphate buffered 
saline (PBS) and then incubated overnight with primary antibodies diluted in 3% normal 
goat serum (NGS) and 0.05% Triton X-100 in PBS. The antibodies were the following: 
mouse anti-S6 protein (Cell Signaling, #2317), rabbit anti-phosphorylated-S6 protein 
(Cell Signaling, #2215), guinea pig anti-vGlut1 (1:500, Synaptic System, 135 304), mouse 
anti-Homer1 (1:200; Synaptic System, 160 011), rabbit anti-vGAT (1:500; Synaptic 
System 131 003), mouse anti-Gephryn (1:500; 147 011), rabbit anti-GluA1 (1:500; 
Synaptic Systems, 182 003), rabbit anti-GABAA-2 receptor subunit (1:500; Synaptic 
System, 224 803). After three washes in PBS, neurons were incubated in the same buffer 
with Alexa-conjugated secondary antibodies (1:1500, Invitrogen) and counterstained 
with Hoechst33342 for nuclei detection. Following several washes in PBS, coverslips 
were mounted with Moviol mounting medium. Images were acquired using a 40x 
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objective with a Leica SP8 confocal microscopy (Leica Microsystem, Wetzlar, Germany) 
and the colocalization plugin of ImageJ was used to process images. To perform the 
analysis of synaptic density, basal dendrites of neurons were considered, and the 
colocalization analysis was performed, after threshold subtraction, at the puncta that 
were double-positive for pre- and post-synaptic markers (vGlut1/Homer1 for excitatory 
synapses and vGAT/Gephryn for inhibitory synapses). Only GFP-positive neurons were 
analyzed for experiments with transduced neurons. To identify bona fide synaptic 
boutons, we selected colocalized puncta within an area of 0.1-1 µm2, corresponding to 
the overlapping area of pre-synaptic and post-synaptic proteins. The number of synaptic 
puncta present along 30 µm dendrite tracts starting from the cell body was counted. For 
the analysis of postsynaptic receptors, the threshold signal of Homer1 and Gephyrin was 
overlapped to GluA1 and GABAA-β2 receptors, respectively, and the fluorescence 
intensity was measured only within the colocalization area. Data refer to three 






Data are expressed as means ± SEM or as box plots showing median, mean, 25 to 75 
interquartile range and min to max values for number of cells (N) or independent 
preparations, as detailed in the figure legends. Normal distribution of data was assessed 
using the D’Agostino-Pearson’s normality test (n>6) or the Shapiro-Wilk test (n<6). The 
F-test was used to compare variance between two sample groups. To compare two 
experimental groups, either the two-tailed unpaired Student’s t-test or the non-
parametric Mann-Whitney’s U-test was used based on data distribution. To compare 
more than two normally distributed experimental groups, one-way ANOVA (followed by 
the Bonferroni’s multiple comparison test) or repeated measures ANOVA was used. To 
compare more than two non-normally distributed experimental groups, the Kruskal-
Wallis ANOVA was used, followed by the Dunn’s multiple comparison test. Significance 
level was preset to p<0.05. Statistical analysis was carried out using Prism (GraphPad 










As previously described, Depdc5 homozygous knockout is embryonically lethal, with 
prenatal death occurring between E14.5 and E17.5 (Hughes et al., 2017; Marsan et al., 
2016). In line with this observation, when mating heterozygous to heterozygous carriers, 
we never observed Depdc5-/- newborns, but only Depdc5+/+ and Depdc5+/- were safely 
delivered ( De Fusco*, Cerullo* et al., 2020). Depdc5+/- animals failed to recapitulate the 
major traits of the human disease, even if they showed a mild phenotype with 
dysmorphic pyramidal neurons and altered cortical excitability, in the absence of 
spontaneous seizures or increased propensity to epileptic seizures triggered by a single 
dose of pentylenetetrazol (Hughes et al., 2017; Marsan et al., 2016). In this context, we 
characterized the expression of Depdc5 gene in a model of constitutive Depdc5 knockout 
by the insertion of the Tm1a allele (FIG. 5A). RT-qPCR and Western Blotting were 
performed to evaluate the level of Depdc5 mRNA and protein in a whole brain of E12.5 
Depdc5+/+, Depdc5+/- and Depdc5-/- embryos (FIG 5B,C). mRNA levels were halved in 
Depdc5+/- compared to Depdc5+/+ mRNA levels and were reduced by approximately 90% 
in Depdc5-/- (p<0.001, One-Way ANOVA test). On the other hand, Depdc5 protein levels 
were reduced around the 50% in the heterozygous embryos, and completely absent in 
the homozygous (FIG. 5C; p=0.002, Student’s t-test). Thus, despite the presence of 
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residual mRNA in Depdc5-/- embryos, this did not lead to protein translation, indicating 
the efficiency of the Tm1a allele in disrupting Depdc5 gene expression (De Fusco*, 
Cerullo* et al., 2020). We next investigated mTOR activity in Depdc5 constitutive 
heterozygous model by comparing the extent of S6 protein phosphorylation (pS6) in 
Depdc5+/+ and Depdc5+/- by immunoblotting (FIG. 5D). Interestingly, no increase of the 
pS6/S6 ratio was detected when comparing Depdc5+/- and Depdc5+/+. Since the presence 
of ectopic pS6-positive enlarged neurons is a hallmark of FCD type 2 patients, we 
performed an immunostaining on neuronal cultures with a phospho-specific anti-pS6 
antibody (FIG 5E). As for the biochemical analyses, Depdc5+/- neurons were not 
significantly altered in both soma size and pS6/S6 ratio. 
Then, we further investigate the effects of the constitutive heterozygous knockdown of 
Depdc5 on synaptic transmission and intrinsic excitability. In order to characterize both 
excitatory and inhibitory transmissions, we recorded mEPSCs and mIPSCs on Depdc5+/+ 
and Depdc5+/- in 14 DIV cortical neurons. Again, no changes in frequency and amplitude 
of mEPSCs/mIPSCs were observed in Depdc5+/- when compared to Depdc5+/+ (FIG. 6A,B). 
In line with electrophysiological results, we did not observe any change in the synaptic 
density of both excitatory and inhibitory synapses (FIG. 6C, upper panels), as well as in 
the levels of the AMPA receptor subunit GluA1 and GABAA β2 subunit between Depdc5+/- 
and Depdc5+/+cultures (FIG. 6C, lower panels). Similarly, no changes were observed in 
the intrinsic excitability of Depdc5+/- neurons, both in terms of number of APs elicited in 
500 ms and of instantaneous frequency (FIG. 6D). Taken together, these data suggest 
the limit of Depdc5 heterozygous animal to recapitulate the epileptic phenotype 
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observed in patients, and the need to loose heterozygosity in order to induce 
hyperactivation of mTORC1 and induce all the morphological and physiological 





Figure 5. Characterization of the constitutive Depdc5 knockdown model. A. Schematic 
representation showing the insertion cassette of the Tm1a allele carried by Depdc5 mouse. B. 
Bar plot showing Depdc5 mRNA levels in Depdc5+/+, Depdc5+/- and Depdc5-/- embryos (n=4). C. 
Representative Western Blot image (left) and corresponding bar plot (right) showing Depdc5 
protein levels in Depdc5+/+, Depdc5+/- and Depdc5-/- embryos (n=5). D. Representative Western 
Blot image (left) and quantification (right) of the pS6 levels in Depdc5+/+ and Depdc5+/- in 14 DIV 
cortical neurons (D; n= 6 embryos). E. Representative confocal image of βIII-tubulin, pS6 and S6 
staining in Depdc5+/+ and Depdc5+/- (left). Bar plot showing soma size, and the fluorescent 
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intensity of pS6/S6 ratio in Depdc5+/+ and Depdc5+/- (n = 6 plates from 3 embryos per genotype). 
Data are expressed as means ± SEM with individual experimental points. *p<0.05; ***p<0.001, 

















Figure 6. Depdc5+/- model fails to recapitulate the epileptogenic phenotype observed in patients. 
A. Representative traces of mEPSCs recorded in Depdc5+/+ and Depdc5+/- in 14 DIV cortical 
neurons (left). Box plot showing the mEPSCs mean firing frequency and amplitude in Depdc5+/+ 
(n=17) and Depdc5+/- (n=15) neurons (right). B. Representative traces of mIPSCs recorded in 
Depdc5+/+ and Depdc5+/- in 14 DIV cortical neurons (left). Box plot showing the mIPSCs mean 
firing frequency and amplitude in Depdc5+/+ (n=12) and Depdc5+/- (n=12) neurons (right). C. 
Upper left panel: Representative confocal images of pre/post-synaptic markers vGlut and 
Homer1 and box plot of the linear density of excitatory synaptic boutons quantification in 
Depdc5+/+ and Depdc5+/- neurons. Upper right panel: Representative confocal images of 
pre/post-synaptic markers vGAT and Gephryn and box plot of the linear density of inhibitory 
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synaptic boutons quantification in Depdc5+/+ and Depdc5+/- neurons. Lower left panel: 
Representative confocal images of the GluA1 AMPA receptor subunit at the excitatory synaptic 
and box plot of GluA1 AMPA receptor subunit fluorescence intensity boutons quantification in 
Depdc5+/+ and Depdc5+/-. Lower right panel: Representative confocal images of GABAA β2 
receptor subunit at the inhibitory synaptic boutons and box plot of GABAA β2 receptor subunit 
fluorescence intensity boutons quantification in Depdc5+/+ and Depdc5+/-. D. Representative 
traces of action potential induced by injection of 270 pA for 500 ms in Depdc5+/+ and Depdc5+/- 
neurons (left). Mean number of APs evoked at increasing level of inject current and 
instantaneous frequency in Depdc5+/+ (n= 22) and Depdc5+/- (n= 22) neurons. All measurements 
were taken from n = 3 independent preparations. For histology, dendrites from at least 10 
neurons per each preparation were analysed. Data are expressed as box plot and as means ± 
SEM. Student's t-test/Mann Whitney's U-test/ ANOVA for repeated measures. Scale bar: 10 µm 




















5.2 Overcoming the limitations of the Depdc5+/- mouse model: 
generation and validation of the Depdc5 conditional knockout 
mouse 
 
Given the evident limitations of the Depdc5+/- mouse model to recapitulate the main 
features of the DEPDC5-related pathological phenotype and the need of heterozygosity 
loss to trigger the severe effects observed in DEPDC5 deficiency cases, we decided to 
focus our attention on the characterization of a conditional knockout mouse model of 
Depdc5 by using the Cre/LoxP system (kindly provided by dr. Stephanie Baulac, Paris 
Brain Institute - Institut du Cerveau – ICM). Indeed, once obtained primary cortical 
neurons from Depdc5-floxed pups, we infected them with lentiviral vectors expressing 
either inactive (Depdc5ΔCre) or active (Depdc5Cre) Cre-recombinase at 7 DIV and 
performed the experiments at 14 DIV (FIG. 7A).  
We first evaluated the level of Depdc5 mRNA by qRT-PCR analysis in Depdc5ΔCre and 
Depdc5Cre cortical neurons. We found that cortical neurons infected with lentivirus 
expressing active Cre-recombinase showed a ≈95% reduction in Depdc5 mRNA levels 
compared to neurons infected with ΔCre-recombinase (p<0.001, Student’s t-test; FIG. 
7B), indicating the effective cKO of Depdc5 through the Cre/LoxP system. In addition, 
Western Blot analysis also confirmed the virtual absence in Depdc5 protein levels in 





Figure 7. Experimental time course and validation of the Depdc5 cKO model. A. Representative 
scheme of the experimental design. B. Bar plots showing Depdc5 mRNA levels in Depdc5ΔCre and 
Depdc5Cre neurons, respectively (n=4 independent preparations) C. Representative Western Blot 
image (left) and corresponding bar plot of Depdc5 protein levels in Depdc5ΔCre and Depdc5Cre 


















Since Depdc5 is a component of the GATOR1 complex, an upstream inhibitor of mTORC1 
complex, its deletion alters the regulation of the mTORC1 pathway. To evaluate the 
effect of Depdc5 cKO on this pathway, we checked for the phosphorylation level of the 
ribosomal protein S6 (pS6) via S6K1, that is one of the major parameter used to evaluate 
the level of mTORC1 activation. Indeed, Depdc5Cre neurons displayed a significant 
increase of pS6 compared to Depdc5ΔCre neurons, while the ratio S6/actin did not change 
(p=0.03, Student’s t-test; FIG. 8A,B). This indicated that the increase in the pS6 level is 
due to an enhanced phosphorylation by mTORC1, rather than an increase in the protein 
translation process (FIG. 8B).  We also immunostained neurons with the pS6 and S6 
antibodies (FIG. 8C,D) and, in line with the biochemical results, we observed an increase 
in the Depdc5Cre pS6/S6 fluorescence intensity ratio (p=0.01, Student’s t-test) compared 
to Depdc5ΔCre neurons. Moreover, in Depdc5Cre neurons, we detected a significant 
increase soma size (p=0.03, Mann-Whitney’s U-test), suggesting the presence of 
morphological alterations in vitro due to mTORC1 hyperactivation (FIG. 8C,D). Finally, 
we also tested whether the observed increase in S6 protein phosphorylation was 
actually linked to mTOR hyperactivation. To verify this hypothesis, we treated both 
Depdc5ΔCre and Depdc5Cre neurons with rapamycin (100 nM; FIG. 8E,F). Interestingly, we 
observed a significant rescue of the Depdc5Cre phenotype in rapamycin-treated neurons, 
with strong reduction of pS6 levels that became indistinguishable from those of 
rapamicyn-treated Depdc5ΔCre controls (p<0.001, 2-Way ANOVA test FIG. 8F). Taken 
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together, the data suggest that Depdc5 cKO is required to induce hyperactivation of 




Figure 8. Depdc5Cre neurons display hyperactivation of mTORC1 pathway and increase in soma 
size. A. Representative image of Western Blot of S6 phosphorylation in Depdc5ΔCre and Depdc5Cre 
neurons. B. Bar plot representing the pS6/S6 (left) and S6/Actin ratio (n=4 independent 
preparations). C. Representative confocal image of GFP, pS6 and S6 immunofluorescence in 
Depdc5ΔCre and Depdc5Cre neurons. D. Box plot showing soma size and pS6/S6 ratio in Depdc5ΔCre 
(n=33) and Depdc5Cre (n=39) neurons. E. Representative image of Western Blot of S6 
phosphorylation in Depdc5ΔCre and Depdc5Cre neurons treated with vehicle (DMSO) and 
Rapamycin, respectively. F. Bar plot representing the pS6/S6 ratio (n=7 independent 
preparations). For histology, neurons from two independent preparations were analyzed. 
*p<0.05; **p<0.01; ***p<0.001, Student’s t-test/Mann-Whitney’s U-test/2-Way ANOVA test. 






5.4 The Depdc5 conditional knockout induces an increase in 
excitatory transmission  
 
Imbalance between excitatory and inhibitory synaptic transmission is believed to be at 
the basis of most epileptic phenotypes (Bozzi et al., 2018; Stafstrom & Carmant, 2015). 
In the central nervous system, the mTORC1 signalling cascade is involved in the 
regulation of different neural processes that include neuronal differentiation, neurite 
outgrowth and synaptic formation during neuronal development (Bockaert & Marin, 
2015; Laplante & Sabatini, 2012; Lasarge & Danzer, 2014). In particular, the balance 
between excitatory and inhibitory synaptic transmission have been demonstrated to be 
altered when mTORC1 activity is dysregulated  De Fusco*, Cerullo* et al., 2020). In order 
to investigate this aspect, we asked whether the conditional Depdc5 knockout could 
alter excitatory synaptic transmission in vitro. Thus, we performed electrophysiological 
recordings of mEPSCs and mIPSCs in in Depdc5ΔCre and Depdc5Cre 14 DIV cortical neurons. 
Interestingly, Depdc5Cre neurons showed a significant increase in both mEPSCs 
amplitude (p<0.001, Student’s t-test) and mEPSCs frequency (p=0.034, Student’s t-test) 
with respect to control Depdc5ΔCre neurons (FIG. 9A,C), in the absence of any changes in 
the frequency and amplitude of mIPSCs (FIG. 9B,D). These data further confirm the key 






Figure 9. Conditional KO of Depdc5 has a strong effect on spontaneous excitatory transmission, 
without affecting spontaneous inhibitory transmission. A,B. Representative traces of mEPSCs 
(left) and mIPSCs (right) recorded in Depdc5ΔCre and Depdc5Cre primary cortical neurons. C. Upper 
panels: box plot showing mEPSC amplitude and frequency in Depdc5ΔCre (n=18) and Depdc5Cre 
neurons (n=17). Lower panels: corresponding cumulative curves of amplitude and inter-event 
interval distribution of mEPSCs. D. Upper panels: box plot showing mIPSC amplitude and 
frequency in Depdc5ΔCre (n=19) and Depdc5Cre (n=18). Lower panels: corresponding cumulative 
curves of amplitude and inter-event interval distribution of mIPSCs. All measurements were 
taken from n=3 independent preparations. Data are expressed as box plots. **p<0.01; 
***p<0.001, Student’s t-test. 
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5.5 Conditional knockout of Depdc5 increases charge and alters 
the kinetics of mEPSCs 
 
Depdc5 deficiency affects miniature excitatory postsynaptic currents, not only by 
increasing amplitude and frequency, but also by affecting charge and kinetics of the 
events ( De Fusco*, Cerullo* et al., 2020). Indeed, in Depdc5Cre neurons we observed and 
significant increase of the total charge transferred by the mEPSCs (p= 0.004, Student’s 
t-test) when compared to the Depdc5ΔCre control (FIG. 10C). This is in line with the 
observed increase in amplitude, indicating an increase in the quantal size of 
neurotransmitter. Moreover, we observed a reduction in the 10-90 rise time (p<0.001, 
Mann-Whitney’s U-test) indicating a more rapid release of the neurotransmitter 
quantum compared to the Depdc5ΔCre control (FIG. 10C). No differences in the mIPSCs 









Figure 10. Depdc5 conditional KO alters mEPSC charge and 10-90 rise time. A,B. Representative 
waveforms of mEPSCs and mIPSCs recorded in Depdc5ΔCre and Depdc5Cre primary cortical 
neurons. C. Box plot showing the charge (left), the 10-90 rise time (middle) and 80% decay time 
(right) parameter of mEPSCs in Depdc5ΔCre (n=18) and Depdc5Cre (n=17). D. Box plot showing the 
charge (left), 10-90 rise time (middle) and 80% decay time (right) of mIPSCs in Depdc5ΔCre (n=19) 
and Depdc5Cre (n=18). All measurements were taken from n=3 independent preparations. Data 









5.6 Increase in number of excitatory synapses and postsynaptic 
receptor expression following cKO of Depdc5 
 
To verify whether the changes in mEPSC frequency could be linked to variations in 
synaptic density, we decided to analyze the distribution of mature excitatory synapses 
unambiguously identified by double immunolabeling for the pre/postsynaptic markers 
vGlut1 and Homer1 (FIG. 11A, left). In agreement with the electrophysiological data, a 
significant increase in the density of excitatory synaptic synapses was observed in 
Depdc5Cre neurons (p<0.001, Student’s t-test; Fig. 11B, left) when compared to 
Depdc5ΔCre neurons, in parallel with the increase in mEPSC frequency. To identify mature 
inhibitory synapses, we performed a double immunostaining for the pre/postsynaptic 
markers vGAT and Gephriyn (FIG. 11A, right). In line with the previous 
electrophysiological evidence, no genotype-dependent difference in inhibitory synaptic 
density was observed (FIG. 11B, right).  
We further investigated the expression of the major AMPA receptor subunit GluA1 at 
Homer-positive puncta, to find a possible correlation with the observed changes in 
mEPSC amplitude and charge (FIG. 11C, left). Interestingly, we found that Depdc5Cre 
neurons displayed a significant increase in GluA1 fluorescence intensity compared to 
Depdc5ΔCre neurons (p<0.001, Student’s t-test; FIG. 11D, left). We finally evaluated the 
expression of the GABAA β2 receptor subunit in Gephyrin-positive puncta (FIG. 11C, 
right), but no genotype-dependent difference could be found, in line with the 
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electrophysiological data (FIG. 11D, right). Overall, these data indicate a strong effect of 
Depdc5 cKO on synaptic connectivity specifically affecting excitatory synapses, while 






Figure 11. Depdc5Cre cortical neurons display an increase in the number of excitatory synaptic 
puncta and in the expression of the AMPA GluA1 receptor subunit. A. Representative confocal 
images of Depdc5ΔCre and Depdc5Cre excitatory synaptic puncta identified by double 
immunostaining for vGlut1/Homer (left) and inhibitory synaptic puncta identified by double 
immunostaining for vGAT/Gephyrin (right). B. Box plots showing the quantification of the linear 
density of excitatory (left) and inhibitory (right) boutons in Depdc5ΔCre and Depdc5Cre networks, 
respectively. C. Representative confocal images of the AMPA GluA1 receptor subunit at 
excitatory synapses (left) and of the GABAA β2 receptor subunit at inhibitory synapses (right) in 
Depdc5ΔCre and Depdc5Cre neurons, respectively. D. Box plots showing the fluorescent intensity 
of the AMPA GluA1 receptor subunit (left) and the GABAA β2 receptor subunit (right) in 
Depdc5ΔCre and Depdc5Cre neurons. For the analysis, dendrites of 20 neurons from two 












5.7 Depdc5 cKO cortical neurons exhibit increased intrinsic 
excitability 
 
It is known that the dysregulation to the mTORC1 pathway is linked to alteration in 
intrinsic excitability ( De Fusco*, Cerullo* et al., 2020; Ribierre et al., 2018). In order to 
investigate this aspect, we performed electrophysiological recordings in current-clamp 
configuration to evaluate the passive and active properties of Depdc5ΔCre and Depdc5Cre 
morphologically identified cortical pyramidal neurons. When analyzing the firing rate 
versus injected current curves in Depdc5ΔCre and Depdc5Cre neurons (FIG. 12A), we 
observed an increased in the number of APs elicited during the 500 ms of current 
injection and in the instantaneous firing frequency in Depdc5Cre neurons, indicating an 
increased intrinsic excitability (FIG. 12C). Interestingly, both Depdc5ΔCre and Depdc5Cre 
did not exhibit altered passive and active properties from the phase-plane plot 
waveform analysis of the first elicited AP (FIG. 13A,B, Table 1) except for a decrease in 
the rheobase, i.e., in the minimum injected current needed to elicit the first AP (FIG. 
13C). So far, these data are consistent with a condition of hyperexcitability induced by 








Figure 12. Depdc5 cKO pyramidal neurons exhibit an increased intrinsic excitability. A. 
Representative recordings of APs induced by the injection of 270 pA for 500 ms in both 
Depdc5ΔCre and Depdc5Cre neurons and representative scheme of increasing injected current 
steps lasting 500 ms. B. Representative recordings of 20 APs evoked by 5-ms current step 
injection at 80 Hz used to identify excitatory neurons. Failures are labeled with #. C. Mean 
number of APs evoked by the 500 ms increasing current steps in Depdc5ΔCre (n=16) and Depdc5Cre 
(n=18) primary pyramidal neurons (left) and instantaneous AP frequency (right). All 
measurements were taken from n=3 independent preparations. Data are expressed as means ± 








Figure 13. Depdc5 cKO does not lead to marked alterations of passive and active membrane 
properties. A,B. Representative AP (left), dV/dt versus time plot (middle) and AP phase plot 
(right) obtained from Depdc5ΔCre and Depdc5Cre cortical neurons. C. Box plots showing Vthreshold, 
Rheobase, APpeak and Max Rising Slope parameters determined in Depdc5ΔCre (n=16) and 
Depdc5Cre (n=18) cortical neurons. All measurements were taken from n=3 independent 























Vrest (mV) -49.38 -51.11 0.29 
Cin (pF) 41.98 41.84 0.50 
Rin (MΩ) 215.6 227.8 0.70 
Rheobase (pA) 209.4 157.2 0.01* 
Vthreshold (mV) -31.75 -32.22 0.84 
Halfwidth (ms) 1.82 1.72 0.68 
AP peak (mV) 28.21 27.62 0.87 
Max rising slope (mV/ms) 92.61 94.93 0.88 
Max repol. Slope (mV/ms) -27.95 -30.32 0.53 
Phase slope (ms-1) 8.91 8.20 0.59 
 
Data are expressed as means ± SEM. *p<0.05; Student’s t-test/Mann-Whitney’s U-test 
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5.8 Depdc5 does not affect PPR and synchronous release in 
excitatory and inhibitory synapses 
 
Given the strong effect of Depdc5 cKO in triggering excitatory synaptic transmission, we 
asked whether it could have an effect on evoked excitatory and inhibitory postsynaptic 
currents (eEPSCs/eIPSCs) and short-term plasticity (STP) paradigms thereof. To 
investigate a possible effect on the functional properties of both type of synapses, we 
generated two types of primary cortical cultures. For analyzing eEPSCs and STP at the 
level of the excitatory transmission, we generated autaptic cell cultures (FIG. 14A), in 
which the applied stimulus and the recording evoked currents occur on the same 
neuron. For the inhibitory system, instead, we used a low density culture (FIG. 14C), in 
which an external stimulator was positioned on the putative presynaptic neuron, 
injecting current in a range of 200-500 µA. Interestingly, no significant changes in eEPSC 
and eIPSC amplitude were observed for both synapses in Depdc5ΔCre and Depdc5Cre 
cortical neurons (FIG. 14E,F; left panels). The STP response to paired stimuli was 
analyzed as the ratio between two consecutive currents (I1 and I2) evoked at increasing 
inter-pulse intervals (from 20 ms to 1 s; paired-pulse ratio or PPR). However, no 
difference in the PPR ratio at all the tested interpulse intervals was observed in both 
excitatory and inhibitory synapses from Depdc5ΔCre and Depdc5Cre (FIG. 14E,F; right 
panels). Since paired pulse plasticity is a pure presynaptic event, this result could 
indicate that Dedpc5 cKO, while specifically altering synaptic connectivity of the 
excitatory system, has no presynaptic effects in both excitatory and inhibitory synapses. 
76 
  
Nevertheless, in order to deepen this hypothesis, we analyzed if the synchronous 
release of glutamate and GABA could be affected by the cKO of Depdc5. Thus, we 
estimated the quantal parameters of neurotransmitter release, i.e., the readily 
releasable pool (RRP) and the probability release (Pr) of any given synaptic vesicle in the 
RRP using cumulative amplitude analysis. Both excitatory and inhibitory synapses were 
stimulated at 40 Hz for 1s to obtain a cumulative amplitude curve (FIG. 15A,B). The 40 
Hz train stimulation induced a significant depression of ePSCs that become evident 
during the stimulation period irrespective of the amplitude of the first current in the 
train. Thus, cumulative profile of the ePSC amplitude presents a rapid rise followed by a 
slower linear increase, indicating the equilibrium between depletion and constant 
replenishment of the RRP (FIG. 15C,D). The cumulative amplitude curve profile of the 
data points between 0.5 and 1 s were fitted by linear regression and backextrapolated 
to time 0 to obtain RRP value. The Pr was obtained by the ratio between the amplitude 
of the first event and the RRP. Again, no significant changes were observed in both of 
synapse types in terms of PPR and Pr (FIG. 15E, F), strengthening the hypothesis that 
Depdc5 cKO affect excitatory synapses only at the post-synaptic level, in line with the 
previous data concerning the excitatory synaptic transmission. On the other hand, 
Depdc5 cKO does affect inhibitory synapses, neither at the presynaptic nor at the 






Figure 14. Depdc5 cKO does not affect the presynaptic properties of both excitatory and 
inhibitory synapses. A,B. Representative images of autaptic neurons and representative 
recordings of two consecutive excitatory currents (I1 and I2) evoked at 50 ms interpulse interval 
in Depdc5ΔCre and Depdc5Cre neurons. C,D. Representative images of pre- and postsynaptic 
neurons in low density cultures and representative recordings of two consecutive inhibitory 
currents (I1 and I2) evoked at 50 ms interpulse interval in Depdc5ΔCre and Depdc5Cre. E. Box plot 
of the amplitude of eEPSCs (left) and paired-pulse ratio (I2/I1; right) of excitatory synapses at 
interpulse intervals from 20 ms to 1 s in Depdc5ΔCre (n=6) and Depdc5Cre (n=11) neurons. F. Box 
plot of the amplitude of eIPSCs (left) and paired-pulse ratio (I2/I1; right) of inhibitory synapses 
at interpulse intervals from 20 ms to 1 s in Depdc5ΔCre (n=16) and Depdc5Cre (n=12) neurons. All 
measurements were taken from n=3 independent preparations. Data are expressed as means ± 




Figure 15. Depdc5 cKO does not impair synchronous release of glutamate and GABA. A,B. 
Representative traces of train stimulation at 40 Hz for 1 s in excitatory (A) and inhibitory (B) 
Depdc5ΔCre and Depdc5Cre synapses. C. Cumulative eEPSC amplitude curve (left) and plot of 
normalized eEPSC amplitude versus time (right) during repetitive stimulation at 40 Hz for 
Depdc5ΔCre (n=7) and Depdc5Cre (n=8) D. Cumulative eIPSC amplitude curve (left) and plot of 
normalized eIPSC amplitude versus time during repetitive stimulation at 40 Hz for Depdc5ΔCre 
(n=6) and Depdc5Cre (n=8). E. Size of RRP (left) and calculated Pr (right) of excitatory synapses in 
Depdc5ΔCre (n=7) and Depdc5Cre (n=8) neurons. F. Size of RRP (left) and calculated Pr (right) of 
inhibitory synapses in Depdc5ΔCre (n=6) and Depdc5Cre (n=8) neurons. All measurements were 
taken from n=3 independent preparations Data are expressed as means ± SEM, Student’s t-






Over the last decade, mutations in genes encoding for components of the amino acid 
sensing branch of the mTORC1 pathway have been involved in different forms of 
inherited focal epilepsies. In particular, mutations in the GATOR1 components, NPRL2/3 
and DEPDC5 have gained more and more attention, emerging as the common cause of 
FEs with a phenotype ranging from sporadic early-onset epilepsies with cognitive 
impairment to familial focal epilepsies, and SUDEP. Among them, alterations in the 
DEPDC5 gene represent the 37% of total FE cases (Baldassari et al., 2019). In view of the 
need of finding new therapeutic strategies for treating epilepsy, DEPDC5 has soon 
become one of the most promising therapeutic targets. Nevertheless, some aspects of 
Depdc5 deficiency on neuronal activity have still to be clarified (Myers & Scheffer, 2017). 
So far, different animal models have been generated in order to investigate the Depdc5-
related epileptic phenotype, which is mainly characterized by an increase in the mTOR 
pathway activation and alteration in the cortical cytoarchitecture with abnormal and 
dysmorphic neurons, reminiscent of the patients’ condition affected by FCD (Marsan & 
Baulac, 2018). Along with these altered morphological features, physiological alterations 
have also been described. In particular, animal models for Depdc5-deficiency showed 
excitatory/inhibitory imbalances and impaired intrinsic excitability  (De Fusco*, Cerullo* 
et al., 2020; Klofas et al., 2020; Ribierre et al., 2018). While the heterozygous model for 
the Depdc5 fails to recapitulate these aspects, it has become evident that loss of 
80 
  
heterozygosity is needed to trigger the Depdc5 related-epileptic phenotype. Indeed, 
recent studies showed the occurrence of second-hit DEPDC5 mutation variants in 
resected brain samples from individuals with FCD (Baldassari et al., 2019; Sim et al., 
2019). Moreover, the temporal dynamics of Depdc5-loss is a fundamental part of the 
epileptogenic process, suggesting an important neurodevelopmental role for Depdc5 
(De Fusco*, Cerullo* et al., 2020). In this context, in order to overcome the problem of 
heterozygosity and have a more reliable Depdc5-deficiency model to deeply investigate 
its physiological effect on synaptic transmission and plasticity, we decided to use the 
Cre/LoxP system on Depdc5-floxed mice. In our previous work, in which we applied a 
post-transcriptional gene silencing strategy, we were able to induce an acute 
knockdown of Depdc5 mRNA and protein, with both levels decreased around ≈80% 
compared to controls (De Fusco*, Cerullo* et al., 2020).  Even though with this strategy 
Depdc5 mRNA and protein levels were already largely reduced to a more than 
acceptable percentage, we decided to adopt a conditional knockout strategy by applying 
the Cre/LoxP system. With this strategy, the reduction of Depdc5 mRNA and protein 
levels were even larger, around ≈ 95%, representing a more reliable tool and model to 
study Depdc5 loss effect in a more precise way both in vitro and in ex vivo/in vivo 
conditions. This reduction, in parallel with an increase in the mTOR activity revealed by 
the higher levels of pS6, is linked to an augmented excitatory neuron connectivity, 
characterized by increased amplitude and frequency of mEPSCs, together with an 
increase in the density of excitatory synapses and in the expression of postsynaptic 
glutamate receptors. The severe phenotype we have observed is in line with what we 
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previously shown in the acute Depdc5 knockdown model by RNA interference. In this 
context, our data are in agreement with the excitatory/inhibitory imbalance and 
increased intrinsic excitability observed in other different Depdc5-defiency models. For 
example, the mosaic knockdown of Depdc5 model showed abnormal dendritic tree 
growth in parallel with increased amplitude of sEPSCs and increased intrinsic excitability 
(Hu et al., 2018; Ribierre et al., 2018). On the other hand, Ribierre and colleagues found 
a reduced frequency of the spontaneous events. This is possibly due to the increased 
cell size with increased cell capacitance of electroporated neurons that may account for 
the reduced firing patterns. Nevertheless, the higher gain of firing frequency (slope F-I 
curve) above threshold of the electroporated Depdc5 knockout neurons is consistent 
with an increase in the responsiveness to current input changes, possibly due to an 
alteration of ionic conductances (Ribierre et al., 2018). On the contrary, our model of 
Depdc5 cKO neurons presents an increased intrinsic excitability in the absence of 
changes in cell capacitance; this difference is likely due to the in vitro conditions of our 
experiment. 
Furthermore, our data demonstrate that only the excitatory system is affected by the 
Depdc5 loss, while the inhibitory system is not significantly perturbed. This differs from 
previous observations in Zebrafish and in a distinct Depdc5Emx1 cKO mouse in which 
Depdc5 deficiency was associated with dysregulation of the GABAergic network 
development (Swaminathan et al., 2018; Klofas et al., 2020). In particular, layer V 
pyramidal neurons of Depdc5Emx1 cKO mice show decreased mIPSC responses,  
suggesting a possible functional impairment in the postsynaptic response to GABAergic 
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inputs (Klofas et al., 2020). These discrepancies could be ascribed to the time course of 
Depdc5 silencing, to species-specific differences and to the different experimental 
approach (in vitro vs. ex vivo) used in the experiments. All together, these data suggest 
that the loss of Depdc5 heterozygosity can trigger a strong excitatory/inhibitory 
imbalance and an increase in intrinsic excitability that can both contribute to the 
epileptogenic phenotype.  
Given the pivotal role in altering synaptic connectivity and intrinsic excitability, we 
wondered of a possible effect of Depdc5 deficiency in synaptic plasticity. Protein 
synthesis is required for persistent forms of synaptic plasticity, including long-term 
potentiation (LTP). The mTOR pathway is known to be a key regulator of LTP-related 
protein synthesis by modulating the translational capacity and facilitating the synthesis 
of specific components of the protein synthesis machinery (Tsokas et al., 2007). 
Moreover, it was already reported that the mTOR pathway participates in the 
mechanism of LTP the CA1 in the hippocampus and that LTP in this region is a rapamycin-
sensitive (Cammalleri et al., 2003).  
Thus, on the basis of the reported involvement of mTOR in the mechanism of LTP and 
the effect of its dysregulation on synaptic transmission, we asked whether Depdc5 loss 
could have an impact on short-term plasticity. We then investigated the physiological 
impact of Depdc5 cKO in quantal parameters, release dynamics and STP. However, no 




Taken together, our data suggest that the Depdc5 loss induces mostly a change at the 
level of the synaptic connectivity, by increasing the number of excitatory synapses and 
enhancing excitatory synaptic transmission mostly at a postsynaptic level. Indeed, the 
increase in both amplitude and charge parameters could confirm this assumption, while 
the increase in the number of excitatory synaptic puncta is responsible for the increase 
in the mEPSCs frequency. Nevertheless, this hypothesis should be verified by further 
experiments evaluating possible alterations in postsynaptic dynamics.  
The specific molecular mechanism underlying these functional changes triggered by 
Depdc5 loss is still unclear. Interestingly, mTOR is known to have a main role in the 
regulation of the autophagic process. This is a very fundamental mechanism for cell 
physiology, since it regulates the turnover of the organelles and proteins through the 
endosomal system (Glick et al., 2010). In recent years, a large body of experimental 
evidence showed that mTOR-mediated autophagy inhibition could reduce synaptic 
pruning and induce internalization of glutamate receptors. In our previous model of 
Depdc5 acute knockdown, we observed a significant increase in the nerve terminal 
endosomal area in Depdc5KD neurons compared to the control, suggesting the existence 
of a defective autophagic process due to mTOR hyperactivation (De Fusco*, Cerullo* et 
al., 2020). Indeed, autophagy is critically involved in the molecular mechanisms 
underlying epileptogenesis and seizure-induced neuronal alterations. Altered 
autophagy reduces GABA signaling, blocks NMDAR and AMPAR degradation and induces 
abnormal glutamate signaling and Ca2+ influx (Limanaqi et al., 2020.). Furthermore, it is 
known that activation of mTORC1 affects synaptic activity by favoring the expression 
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and surface localization of AMPA receptor subunits GluA1 e GluA2, an effect that is 
inhibited by rapamycin (Wang et al., 2006). All this evidence represents possible 
scenarios through which the Depdc5 loss, acting as a trigger for mTORC1 activity, can 
induce the observed phenotypes, from imbalanced excitatory/inhibitory 
neurotransmission to increased intrinsic excitability, all features that underlie 
epileptogenesis.  
Technical and experimental limitation of the project. In this PhD project we show the 
effect of Depdc5 cKO on primary cortical neurons by applying the Cre/LoxP technique. 
Even though this approach cannot be compared to the biallelic 2-hit mutational 
mechanism observed in patients (Ribierre et al., 2018), this subacute effect of Depdc5 
loss on primary cultures still leads to a solid neuronal phenotype. Indeed, with this 
model we were able to highlight the importance of the “loss of heterozygosity” and the 
neurodevelopmental role of Depdc5. The latter element is fundamental to trigger the 
changes in synaptic transmission, connectivity and structure that are associated with 
mTOR hyperactivation and related epileptogenesis, as shown in this dissertation and in 
our previous model of Depdc5 acute knock-down (De Fusco*, Cerullo* et al., 2020).  
Despite the severe phenotype observed in the Depdc5 cKO model, characterized 
through electrophysiological, biomolecular and biochemical experiments, the important 
missing piece is the understanding of specific mechanism of action of Depdc5 loss. We 
still need (i) to clarify whether the observed phenotypes are due to alterations at the 
transcriptional level, in the  interactions with different signal transduction systems or to 
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complex dysregulations in protein expression and (ii) to define how Depdc5 loss-of-
function can influence these processes.  
The mTOR signaling pathway is composed of different upstream and downstream 
regulators that interact one with each other. Thus, understanding the precise 
mechanisms through which the Depdc5 loss impact the activity of the mTOR signaling 







7. Conclusions and future perspectives 
 
 
In this dissertation we showed how Depdc5 cKO induces a strong alteration of excitatory 
synaptic transmission and intrinsic excitability, two effects that can synergistically 
trigger the epileptogenic process through the establishment of an excitation/inhibition 
imbalance. Moreover, our data suggest that the effect of Depdc5 loss mainly consists of 
an increase of excitatory synaptic connections, with increased postsynaptic glutamate 
receptors, without apparently affecting short-term synaptic plasticity that mostly relies 
on presynaptic mechanisms. Further experiments are still needed to verify this 
hypothesis. Indeed, other STP paradigms and glutamate puff recordings will be 
performed to deepen the role of Depdc5 loss on synaptic plasticity and to assess the 
contribution of Depdc5 to glutamate transmission at the postsynaptic level. Together 
with these electrophysiological data, further biochemical assay, such as biotinylation of 
AMPA receptors will be performed, in order to better characterize the mechanistic role 
of Depdc5 in excitatory synaptic transmission, an important missing piece in the 
understanding of the effects of Depdc5 loss on neuronal activity. Moreover, given the 
pivotal role of mTOR pathway in regulating LTP, it would also be interesting to assess 
the impact of Depdc5 loss on long-term plasticity phenomena, that involve protein 
synthesis and variation in synaptic connectivity. 
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Overall, our data confirm the idea that the loss of heterozygosity, and thus a significant 
increase in mTOR activity, is necessary to trigger the Dedpc5-related epileptogenic 
phenotype that likely consists of a developmental effect at the level of synaptic 
connections that is associated with a strong E/I imbalance and intrinsic hyperexcitability. 
In this context, our data help to understand the physiological role of Depdc5 and the 
pathomechanisms by which Depdc5 loss triggers epileptogenesis, representing a 
starting point for further investigations and indicating this gene as potential target for 
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